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Background
The incidence of breast cancer increases with age (1). Due 
to improved survival outcomes and life expectancies, by 
2040 around 40% of new breast cancer cases diagnosed per 
year globally, will be in patients aged ≥70 years (2). This 
will have a huge international impact both financially and in 
terms of service provision. 
Despite this, most research in the field remains targeted 
at younger patients. Age-specific guidelines are not widely 
referred to and guidelines which do allude to the older 
woman as an individual are based solely on conventional 
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factors, such as grade and size of tumour, nodal status 
and estrogen receptor (ER) status. The main treatment 
decisions in older (often defined using the age cut-off of 
70 years in a number of studies) women with primary breast 
cancer are regarding (I) primary treatment and (II) adjuvant 
treatment.
Primary treatment
Current guidelines in the UK (3), Europe (4) and worldwide 
(5,6), advise surgery as the first-line treatment of primary 
operable breast cancer, irrespective of age. Historically, 
primary endocrine therapy (PET) has been used in older 
women unfit for surgery, or where the patient declines 
surgery. The International Society of Geriatric Oncology 
and European Society of Breast Cancer Specialists now 
advise that PET should only be offered for patients with 
ER-positive tumours with a limited life expectancy, despite 
optimisation of medical conditions (7). Despite this, figures 
for uptake of PET are reported between 12–40% (8-10). 
Reasons for this are likely to be multifactorial and 
related to patient preferences, consideration of quality 
of life and physical fitness. One reason may be concerns 
over decline in health following surgery, however, there is 
limited evidence in the literature to support or deny the 
claim that functional status and independence decline after 
breast cancer surgery (11). Patients report good satisfaction 
and low treatment morbidity with PET (7). Furthermore, 
surgery and PET have similar survival outcomes for up to 
5 years (10), thus PET appears to be an attractive 
treatment option in some patients. ER positivity is defined 
as staining of ≥1% of tumour nuclei in the sample tested (12). 
Although there is emerging data to suggest that samples 
which stain up to ≤10% ER-positive, behave in the same 
way as <1% ER-positive (13), the previous definition is 
still currently used. Overall, greater than 30% of patients 
with ER-positive primary breast cancer treated by surgery 
relapse despite endocrine therapy (14-16). In addition to 
this, initiation of PET can take weeks to months before any 
clinical benefit is seen and there is an unfortunate group of 
patients who exhibit no response following this. 
Further problems arise in older women with primary 
breast cancer who have ER-negative tumours, of which 
there is little discussion in the current literature. There is 
little evidence to suggest that comorbidity itself is related 
to breast cancer subtype (17); one study has found a slightly 
lower proportion of ER-positive tumours among patients 
with diabetes (18).
Primary surgery is still recommended where possible. 
One alternative option is primary radiotherapy, which may 
present problems in terms of tolerability and side effects. 
Another option may be chemotherapy, however, it would 
be expected that if the patient could not tolerate surgical 
management, this would be the same, if not worse, for 
chemotherapy. Historically, some patients with ER-negative 
tumours received endocrine therapy regardless of receptor 
status (19) although this is no longer recommended (3). 
Adjuvant treatment
No adjuvant treatment is risk-free and risks versus benefits 
of all potential treatments should be discussed with 
an older patient as part of the shared decision-making 
progress. Clearly, with use of multidrug therapy, risk of 
adverse events increases. The largest treatment dilemma 
in older women with regards to adjuvant treatment is 
whether or not they should receive adjuvant chemotherapy, 
especially in patients with ER-negative tumours where 
adjuvant endocrine therapy is not an option. Older patients 
tolerate chemotherapy poorly compared to their younger 
counterparts because of progressive reduction of organ 
function and comorbidities related to age (20). 
A further dilemma is in the treatment of patients with 
human epidermal growth factor receptor 2 (HER2)-
positive disease. Traditionally anti-HER2 therapies are 
offered in combination with chemotherapy. The National 
Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 07 
(RESPECT) trial is a phase 3 randomised trial in patients 
≥70 years randomised to receive either trastuzumab or 
trastuzumab plus chemotherapy. The study has recruited 
275 participants and the results are eagerly awaited (21). 
This could have significant implications for patients with 
HER2-positive disease if the benefit of trastuzumab alone 
is confirmed; meaning that they would only have to face the 
toxicity of a single treatment, which, in this case, has less 
side effects than chemotherapy. 
Although generally, the side effects from adjuvant 
endocrine and radiotherapy are understood to be less 
detrimental than those of chemotherapy, they could be 
extremely significant in the group of patients who suffer 
from them. Studies have reported between 38–50% of 
patient discontinuation endocrine therapy within 5 years 
of surgery (22,23), largely thought to be related to 
intolerable side effects. Fatigue is the most common side 
effect following radiation therapy and affects up to 77% of 
patients (24). 
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Current understanding of breast cancer biology 
Traditionally, we have understood breast cancer to consist 
of four main biological subtypes (Figure 1), with treatment 
plans dependent on subtype. Luminal A and B type tumours 
are more likely to respond to endocrine therapy; basal or 
triple negative breast cancer (TNBC) are most likely to 
benefit from chemotherapy and tumours with HER2 over-
expression should be offered anti-HER2 therapy.
However, it is now recognised that breast cancer is 
a biologically heterogeneous complex of diseases, with 
a spectrum of many subtypes with distinct biological 
features (26). Therefore, treatment plans based on routinely 
measured biomarkers and our current understanding of 
disease subtypes may no longer be adequate.
The correlation between ER positivity and age is well 
documented; ER positivity increases with age with the 
highest proportion of patients with ER-positive tumours in 
the >65–70 years age group (27,28); >80% of older women 
tend to have ER-positive tumours (29), which is considered 
to be a less aggressive phenotype. This association is 
fundamental in the development of PET and adjuvant 
therapies in older women, however, we are now beginning 
to understand that there may be other biomarkers, not 
currently measured routinely in clinical practice, which may 
have importance in determining response to therapy (30).
Other favourable characteristics noted in older women 
with primary breast cancer are lower expression of HER2, 
lower frequency of p53 mutations and overexpression of 
B-cell lymphoma 2 (BCL-2) protein (31). Generally, breast 
cancers in older women appear to be more indolent and 
display less aggressive biological features. These features 
may help to guide treatment decision making where a 
patient may be considering surgery versus PET and when 
deliberating adjuvant therapies.
Some tools to help inform the prognosis and response 
to therapy, primarily in the adjuvant setting, do exist. The 
Nottingham Prognostic Index (NPI) (32), from our group, 
was the first tool of its kind to assess a combination of 
factors, including histological grade which reflects tumour 
biology, together with size of tumour and nodal status 
(time-dependent factors), to inform prognosis following 
surgery. Assessment that is more comprehensive, for example 
Adjuvant! Online (33), which uses more clinico-pathological 
features, has been developed, but recruitment of older 
women in their conception is lacking and the aims of these 
tools are not focused to the treatment dilemmas of the older 
population. Furthermore, these tools do not require unique 
tumour material to be assessed from an individual patient, 
so are not truly personalised to that patient (34).
Overview of Nottingham research programme
Breast cancer research in Nottingham has a longstanding 
international reputation since evolution of the Nottingham 
Grading System and NPI (32). We have experience in the 
study of breast cancer samples since our unit was established 
in 1973. The unit has since developed a unique research 
programme on primary breast cancer in older women.
The cohort
Over a 37-year period (1973–2010), 1,758 older (≥70 years) 
women with early operable (<5 cm, T0–2, N0–1, M0) 
primary breast cancer were managed in a dedicated facility 
in Nottingham. Clinical information was available from 
Figure 1 Patient outcome based on breast tumour biological subtypes (25). ER, estrogen receptor; PR, progesterone receptor; HER2, 
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diagnosis of breast cancer until death or last documented 
follow-up and has been described previously (35,36). 
Histological data in terms of sample at diagnosis and 
surgical excision (SE) specimen (where applicable), is 
available. To the best of our knowledge, this is the largest 
database of this kind, in the literature.
Comparison between older and younger women
From the whole series, 813 patients underwent primary 
surgery and the remaining had non-operative or no 
treatment. It has been possible to construct 575 tissue 
microarrays (TMAs) using the SE samples and a panel of 
25 biomarkers has been assessed in these SE TMAs (37). 
Cluster analysis identified six biological clusters of disease 
in older patients, four of which are consistent with standard 
clusters seen in younger women and one which was 
consistent with “normal-type” of breast tissue. The unique 
cluster, termed “low ER luminal” had high expression of 
luminal cytokeratins (CKs), mucin 1 and HER3 compared 
to the other conventional clusters and had different breast 
cancer specific survival (BCSS) compared to conventional 
clusters (Figure 2).
Primary treatment
In a subset of 1,065 of the cohort, 449 had primary surgery 
and 616 PET. ER was measured by H-score and this was 
used as a continuous variable for analysis, rather than a 
standard cut-off. Patients with tumours with ER H-score of 
>250 (out of 300) (i.e., very ER rich) had equivalent BCSS 
regardless of treatment of primary surgery or PET (P=0.7) 
(Figure 3A), whereas in patients with H-score ≤250, surgery 
produced better BCSS (P<0.001) (Figure 3B) (35).
This suggests that within the group of patients with ER-
positive disease based on standard definitions, there may 
be scope to further subdivide patients by the degree of ER-
positivity.
In the overall cohort, 194 patients had ER-negative 
tumours, 77% of which were treated by primary surgery, 
14.3% with PET (historic treatment), 5.6% with primary 
radiotherapy and supportive treatment only in 3.1% (38). 
Biological analysis did not demonstrate any correlation 
between measurement of PR, HER2 or Ki67 with BCSS, 
contrary to the findings in the patients with ER-positive 
tumours (35). However, compared to the patients with 
ER-positive tumours, patients with ER-negative tumours 
Figure 2 Breast cancer-specific survival of older women with early operable primary breast cancer according to biological clusters (37). ER, 
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have higher rates of Ki67 expression, lower PR and higher 
HER2, consistent with more aggressive tumour biology. 
The majority of those with ER-negative tumours studied 
here, died of breast cancer in contrast to the outcome of 
patients with ER-positive tumours where the majority died 
of non-breast cancer causes.
After a comprehensive systematic literature review on 
the subject (39), a technique to successfully construct TMAs 
from core needle biopsy (CNB) samples was developed by 
us (40). 
It has been possible to construct 693 TMAs from CNB 
samples from the overall cohort. A panel of 18 biomarkers 
has been measured in the majority of the CNB TMAs 
in patients who had ER-positive breast cancer (41). 
Examination of these specimens confirmed the presence of 
the low-ER luminal cluster and identified other biomarkers 
in addition to ER, which were independent predictors 
for BCSS, including PR, Ki67 and mucin 1 (41). It may 
be possible to determine which of these biomarkers help 
predict response to PET. 
Adjuvant treatment 
Findings suggestive of a diversification of biology (with 
differing clinical outcomes) according to age, have also been 
found in patients with HER-2 positive (42) and TNBC (43), 
providing evidence that consideration of the role of biology 
of breast cancer should be made during treatment decision 
making. 
In a comparison study of 130 younger (<70 years) 
patients versus 43 older (≥70 years) patients identified as 
having HER2-postive tumours, there was no difference 
in BCSS, despite minimal use of chemotherapy in the 
older age group, compared to frequent use in the younger 
group (42). Furthermore, when compared to their younger 
counterparts, older women with HER2 overexpressing 
tumours were more likely to have low expression of Ki67 
and high expression of BCL-2. 
These results were replicated in patients with TNBC. 
A total of 127 older women with TNBC were compared 
to 342 younger women. The older patients with TNBC 
had lower expression of Ki67 and basal CK5/6, but higher 
expression of BCL-2 and luminal CK18. There was no 
significant difference in BCSS between younger and older 
women, despite minimal chemotherapy use in the older 
cohort. 
These findings suggest that overall, older women in 
this cohort express a less aggressive phenotype of breast 
cancer, compared to their younger counterparts and provide 
evidence that consideration of the role of biology of breast 
cancer should be made during treatment decision making. 
Future considerations
Fully understanding the biology of breast cancer in older 
women will impact every stage of the treatment pathway 
including primary and adjuvant treatment. For example, 
it may be possible to more accurately identify who will 
respond to endocrine therapy as primary treatment as an 
alternative to surgery, or which patients may not require 
adjuvant therapy. We hypothesise that there is a group of 
older women with breast cancer who will never die from 
their breast cancer due to competing comorbidities and 
being able to identify these patients at diagnosis would have 
a huge influence on their treatment.
A move is underway towards personalised cancer 
treatment, where tumour biology of an individual patient 
is examined to give unique predictive and prognostic 
information. This is extremely important in the setting 
of older women, who may have different treatment goals 
Figure 3 Breast cancer-specific survival of primary breast cancer in older women treated by surgery versus primary endocrine therapy with 
H-score <250 (A) and H-score ≥250 (B).
Survival in months






















Primary endocrine therapy (N=135)
Surgery (N=85)
(Log-rank P value =0.71) 
(Wilcoxon’s P value =0.70)
Survival in months






















Primary endocrine therapy (N=451)
Surgery (N=352)
(Log-rank P value <0.001) 
(Wilcoxon’s P value <0.001)
A B
Annals of Breast Surgery, 2021Page 6 of 8
© Annals of Breast Surgery. All rights reserved. Ann Breast Surg 2021;5:5 | http://dx.doi.org/10.21037/abs-20-130
compared to their younger counterparts; their focus may 
be towards preservation of quality of life rather than 
curative treatment. There are currently a number of 
existing predictive and prognostic tools available for use 
in breast cancer, however, the evidence base for the use of 
these tools specifically in the older population is weak (34). 
Furthermore, these tools have mainly been licensed for use 
in the adjuvant setting following surgery. In the future, we 
expect the development of a tool to analyse an extensive 
panel of biomarkers for an individual patient with primary 
breast cancer, based on their CNB specimen. This would 
generate patient-specific survival outcomes based on their 
individual tumour biology, which would allow them to make 
personalised treatment decisions. 
Some areas of medicine, for example, orthopaedic 
surgery, routinely utilise geriatric assessment (GA) to 
identify patients who may benefit from more detailed 
interventions. GA generally consists of a few major 
components including: medical assessment of current 
diagnoses, medications and nutritional status; assessment 
of physical function, psychological evaluation of mentality 
and mood; social and environmental assessments (44). The 
concept of GA in oncology is recommended (45), however, 
full GA can be time-consuming and may not be useful in all 
cases. Some studies have opted for use of a frailty screening 
assessment to decide who should receive full GA, but which 
tool best serves this purpose remains debatable (46,47). 
A combination of detailed biological assessment, 
alongside some form of GA, would truly personalise breast 
cancer treatment for older women. Given our expanding 
older population as described, the health and economic 
implications of this on a worldwide scale can no longer be 
ignored.
Acknowledgments
Funding: No funding or sponsorship was received for the 
publication of this article. This article was written as part 
of RM Parks’ PhD, supported by a Fellowship funded 
by Nottingham Hospitals Charity, UK and an Honorary 
Fellowship from the Royal College of Surgeons of England. 
The overall project is supported by a grant funding by 
Breast Cancer Research Trust, UK.
Footnote
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/abs-20-130). KLC serves as an unpaid 
editorial board member of Annals of Breast Surgery from 
Aug 2020 to Jul 2022. The other authors have no conflicts 
of interest to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. Elements related 
to the study of participant data was approved by the 
Nottingham Research and Development committee. The 
title of the application was “Development of a molecular 
genetic classification of breast cancer”, project registration 
number: 03HI01, ethics committee number: C1080301.
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and the 
original work is properly cited (including links to both the 
formal publication through the relevant DOI and the license). 
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References




[Accessed: 6th April 2020]. 2020.
2. World Health Organisation. International Agency for 
Research on Cancer. Available online: https://www.iarc.fr 
[Accessed: 24th June 2019]. 2019.
3. National Guideline Alliance (UK). Early and locally 
advanced breast cancer: diagnosis and management. 
London: National Institute for Health and Care Excellence 
(UK); 2018 Jul. NICE Guideline, No. 101.
4. Senkus E, Kyriakides S, Ohno S, et al. Primary breast 
cancer: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v8-30.
5. National Comprehensive Cancer Network. Breast Cancer: 
Early Stage. Version 1. 2016. Available online: https://
www.nccn.org/patients/
6. Kaufmann M, Morrow M, von Minckwitz G, et al. 
Locoregional treatment of primary breast cancer. Cancer 
2010;116:1184-91.
Annals of Breast Surgery, 2021 Page 7 of 8
© Annals of Breast Surgery. All rights reserved. Ann Breast Surg 2021;5:5 | http://dx.doi.org/10.21037/abs-20-130
7. Biganzoli L, Wildiers H, Oakman C, et al. Management 
of elderly patients with breast cancer: updated 
recommendations of the International Society of Geriatric 
Oncology (SIOG) and European Society of Breast Cancer 
Specialists (EUSOMA). Lancet Oncol 2012;13:e148-60.
8. Morgan J, Richards P, Ward S, et al. Case-mix analysis and 
variation in rates of non-surgical treatment of older women 
with operable breast cancer. Br J Surg 2015;102:1056-63.
9. Morgan J, Wyld L, Collins KA, et al. Surgery versus 
primary endocrine therapy for operable primary breast 
cancer in elderly women (70 years plus). Cochrane 
Database Syst Rev 2014;(5):CD004272.
10. Hind D, Wyld L, Beverley CB, et al. Surgery versus 
primary endocrine therapy for operable primary breast 
cancer in elderly women (70 years plus). Cochrane 
Database Syst Rev 2006;(1):CD004272.
11. Parks R. Impact of breast cancer surgery on functional 
status and independence. J Geriatr Oncol 2019;10:S1.
12. Hammond ME, Hayes DF, Dowsett M, et al. 
American Society of Clinical Oncology/College of 
American Pathologists Guideline Recommendations 
for Immunohistochemical Testing of Estrogen and 
Progesterone Receptors in Breast Cancer. Arch Pathol Lab 
Med 2010;134:e48-72.
13. Fujii T, Kogawa T, Dong W, et al. Revisiting the definition 
of estrogen receptor positivity in HER2-negative primary 
breast cancer. Ann Oncol 2017;28:2420-8.
14. Haque MM, Desai KV. Pathways to Endocrine Therapy 
Resistance in Breast Cancer. Front Endocrinol (Lausanne) 
2019;10:573.
15. Piggott L, Silva A, Robinson T, et al. Acquired Resistance 
of ER-Positive Breast Cancer to Endocrine Treatment 
Confers an Adaptive Sensitivity to TRAIL through 
Posttranslational Downregulation of c-FLIP. Clin Cancer 
Res 2018;24:2452.
16. Szostakowska M, Trębińska-Stryjewska A, Grzybowska 
EA, et al. Resistance to endocrine therapy in breast cancer: 
molecular mechanisms and future goals. Breast Cancer Res 
Treat 2019;173:489-97.
17. Søgaard M, Thomsen RW, Bossen KS, et al. The impact of 
comorbidity on cancer survival: a review. Clin Epidemiol 
2013;5:3-29.
18. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. 
Diabetes, metformin, and breast cancer in postmenopausal 
women. J Clin Oncol 2012;30:2844-52.
19. Syed BM, Morgan DAL, Setty T, et al. Oestrogen receptor 
negative early operable primary breast cancer in older 
women—Biological characteristics and long-term clinical 
outcome. PLoS One 2017;12:e0188528.
20. Rossi A, Colantuoni G, Maione P, et al. Chemotherapy 
of Breast Cancer in the Elderly. Curr Med Chem 
2005;12:297-310.
21. U.S. National Library of Medicine. National Surgery 
Adjuvant Study of Breast Cancer (N-SAS BC) 07 
(RESPECT). Available online: https://clinicaltrials.gov/
ct2/show/study/NCT01104935 [Accessed 5th April 2020]. 
ClinicalTrials.gov 2019.
22. Hagen KB, Aas T, Kvaløy JT, et al. Adherence to adjuvant 
endocrine therapy in postmenopausal breast cancer 
patients: A 5-year prospective study. Breast 2019;44:52-
8. Erratum in: Breast. 2019 Jun;45:118. doi: 10.1016/
j.breast.2019.03.007. Epub 2019 Apr 5.  
23. Robinson B, Dijkstra B, Davey V, et al. Adherence to 
Adjuvant Endocrine Therapy in Christchurch Women 
with Early Breast Cancer. Clin Oncol (R Coll Radiol) 
2018;30:e9-e15.  
24. Lipsett A, Barrett S, Haruna F, et al. The impact of 
exercise during adjuvant radiotherapy for breast cancer on 
fatigue and quality of life: A systematic review and meta-
analysis. Breast 2017;32:144-55.
25. Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype 
classification, clinical use and future trends. Am J Cancer 
Res 2015;5:2929-43.
26. Yersal O, Barutca S. Biological subtypes of breast cancer: 
Prognostic and therapeutic implications. World J Clin 
Oncol 2014;5:412-24.
27. Kerlikowske K, Gard CC, Tice JA, et al. Risk Factors That 
Increase Risk of Estrogen Receptor-Positive and -Negative 
Breast Cancer. J Natl Cancer Inst 2016;109:djw276.  
28. Rhodes A, Jasani B, Balaton AJ, et al. Frequency of 
oestrogen and progesterone receptor positivity by 
immunohistochemical analysis in 7016 breast carcinomas: 
correlation with patient age, assay sensitivity, threshold 
value, and mammographic screening. J Clin Pathol 
2000;53:688-96.
29. Diab SG, Elledge RM, Clark GM. Tumor characteristics 
and clinical outcome of elderly women with breast cancer. 
J Natl Cancer Inst 2000;92:550-6.
30. Parks RM, Cheung KL. Clinical relevance of biomarkers 
in oestrogen receptor positive breast cancer. In: Chen GG, 
Tong MCF, van Hasselt CA. editors. Estrogen Receptors: 
Structure, Functions and Clinical Aspects. 1st edition. 
New York, USA: Nova Science Publishers, 2020:53-91.
31. Dimitrakopoulos FI, Kottorou A, Antonacopoulou AG, et 
al. Early-Stage Breast Cancer in the Elderly: Confronting 
an Old Clinical Problem. J Breast Cancer 2015;18:207-17.
Annals of Breast Surgery, 2021Page 8 of 8
© Annals of Breast Surgery. All rights reserved. Ann Breast Surg 2021;5:5 | http://dx.doi.org/10.21037/abs-20-130
32. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic 
index in primary breast cancer. Br J Cancer 1982;45:361-6. 
33. de Glas NA, van de Water W, Engelhardt EG, et al. 
Validity of Adjuvant! Online program in older patients 
with breast cancer: a population-based study. Lancet Oncol 
2014;15:722-9.
34. Gordon-Craig S, Parks RM, Cheung KL. The Potential 
Use of Tumour-Based Prognostic and Predictive Tools in 
Older Women with Primary Breast Cancer: A Narrative 
Review. Oncol Ther 2020;8:231-50.  
35. Syed BM, Al-Khyatt W, Johnston SJ, et al. Long-term 
clinical outcome of oestrogen receptor-positive operable 
primary breast cancer in older women: a large series from 
a single centre. Br J Cancer 2011;104:1393-400.
36. Syed BM, Johnston SJ, Wong DWM, et al. Long-term (37 
years) clinical outcome of older women with early operable 
primary breast cancer managed in a dedicated clinic. Ann 
Oncol 2012;23:1465-71.
37. Syed BM, Green AR, Paish EC, et al. Biology of primary 
breast cancer in older women treated by surgery: 
with correlation with long-term clinical outcome and 
comparison with their younger counterparts. Br J Cancer 
2013;108:1042-51.
38. Syed BM, Morgan D, Setty T, et al. Oestrogen receptor 
negative early operable primary breast cancer in older 
women-Biological characteristics and long-term clinical 
outcome. PloS one 2017;12:e0188528.
39. Albanghali M, Green A, Rakha E, et al. Construction of 
tissue microarrays from core needle biopsies - a systematic 
literature review. Histopathology 2016;68:323-32.
40. Albanghali M. Biology and clinical outcomes of early 
primary breast cancer in older women - a study based 
on core needle biopsy. PhD Thesis. University of 
Nottingham, November, 2016.
41. Parks RM, Albanghali M, Syed BM, et al. Biology of 
Oestrogen-Receptor Positive Primary Breast Cancer in 
Older Women with Utilisation of Core Needle Biopsy 
Samples and Correlation with Clinical Outcome. Cancers 
(Basel) 2020;12:2067. 
42. Syed BM, Green AR, Ellis IO, et al. Human epidermal 
growth receptor-2 overexpressing early operable primary 
breast cancers in older (≥70 years) women: biology and 
clinical outcome in comparison with younger (&lt;70 
years) patients. Ann Oncol 2014;25:837-42.
43. Syed BM, Green AR, Nolan CC, et al. Biological 
characteristics and clinical outcome of triple negative 
primary breast cancer in older women - comparison with 
their younger counterparts. PLoS One 2014;9:e100573.
44. Parks RM, Lakshmanan R, Winterbottom L, et al. 
Comprehensive geriatric assessment for older women 
with early breast cancer - a systematic review of literature. 
World J Surg Oncol 2012;10:88.  
45. Wildiers H, Heeren P, Puts M, et al. International Society 
of Geriatric Oncology consensus on geriatric assessment in 
older patients with cancer. J Clin Oncol 2014;32:2595-603.
46. Biganzoli L, Mislang AR, Di Donato S, et al. Screening 
for Frailty in Older Patients With Early-Stage Solid 
Tumors: A Prospective Longitudinal Evaluation of Three 
Different Geriatric Tools. J Gerontol A Biol Sci Med Sci 
2017;72:922-8.  
47. Valentini A, Federici M, Cianfarani MA, et al. Frailty and 
nutritional status in older people: the Mini Nutritional 
Assessment as a screening tool for the identification of frail 
subjects. Clin Interv Aging 2018;13:1237-44.
doi: 10.21037/abs-20-130
Cite this article as: Parks RM, Green AR, Cheung KL. The 
impact of tumour biology on the management of primary breast 
cancer in older women—based on a research programme in 
Nottingham. Ann Breast Surg 2021;5:5.
